Wells Fargo’s Anbio Biotechnology NNNN Stock Holding History

Wells Fargo’s Portfolio NNNN Stock Details NNNN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-100	Closed	-$2.57K	–	7681
2026 Q1	$2.57K	Hold	100	–	–	﹤0.01%	6219
2025 Q4	$3.01K	Hold	100	–	–	﹤0.01%	6173
2025 Q3	$3.73K	Hold	100	–	–	﹤0.01%	6111
2025 Q2	$3.17K	Buy	+100	New	+$957	﹤0.01%	6150

Other funds holding NNNN

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BFS

Bare Financial Services Gap, Pennsylvania $436M AUM 20.22% 1-Year Est. Return

Wells Fargo's NNNN Position: Q2 2026 in Review

Wells Fargo sold out of Anbio Biotechnology (NNNN) in Q2 2026, closing a stake of 100 shares — an estimated $2.57K sold.

Wells Fargo first reported a position in NNNN in Q2 2025 and held it in 4 quarters. The position peaked at $3.73K in Q3 2025. 12 funds tracked by Wall St. Rank hold NNNN as of Q2 2026.

Wells Fargo reported no remaining Anbio Biotechnology position as of Q2 2026 after selling out during the quarter.
Wells Fargo sold 100 Anbio Biotechnology shares in Q2 2026, an estimated $2.57K.
Wells Fargo first reported a position in Anbio Biotechnology in Q2 2025 and held it in 4 quarters.
Wells Fargo's Anbio Biotechnology position peaked at $3.73K in Q3 2025.
12 funds tracked by Wall St. Rank held Anbio Biotechnology as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.